|
|
||||||||||
|
J Am Coll Cardiol, 2004; 44:276-286, doi:10.1016/j.jacc.2004.03.068 © 2004 by the American College of Cardiology Foundation |

* Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin, USA
Manuscript received January 13, 2004; revised manuscript received March 23, 2004, accepted March 31, 2004.
* Reprint requests and correspondence: Dr. Robert A. Kloner, Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, California 90017, USA.
rkloner{at}goodsam.org
Despite better outcomes with early coronary artery reperfusion for the treatment of acute ST-elevation myocardial infarction (MI), morbidity and mortality from acute myocardial infarction (AMI) remain significant, the incidence of congestive heart failure continues to increase, and there is a need to provide better cardioprotection (therapy that reduces the amount of necrosis that may be coupled with better clinical outcome) in the setting of AMI. Since the introduction of the concept of cardiac protection over a quarter of a century ago, various interventions have been investigated to reduce myocardial infarct size. Intravenous beta-blockers administered in the early hours of infarction were clearly shown to be of benefit. Intravenous adenosine appeared promising for anterior wall AMIs, as did cariporide in some studies. Glucose-insulin-potassium infusion was beneficial in certain subgroups of patients, particularly diabetics. A variety of other medications were studied with negative or marginal results. The best strategy to limit infarct size is early reperfusion with percutaneous coronary stenting or thrombolytic therapy. Stenting is superior and should be adopted whenever there is a qualified laboratory available. Available resources should focus on decreasing time from onset of symptoms to start of reperfusion and maintaining vessel patency. Future studies powered to better assess clinical outcome are needed for adjunctive therapy with adenosine, KATP channel openers, Na+/H+ exchange inhibitors, and hypothermia.
| ||||||||||||||||||||||
This article has been cited by other articles:
![]() |
K. G. Yamazaki, D. Romero-Perez, M. Barraza-Hidalgo, M. Cruz, M. Rivas, B. Cortez-Gomez, G. Ceballos, and F. Villarreal Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H761 - H767. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kloner and R. W. Nesto Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection Circulation, May 13, 2008; 117(19): 2523 - 2533. [Full Text] [PDF] |
||||
![]() |
A. Jahangir, S. Sagar, and A. Terzic Aging and cardioprotection J Appl Physiol, December 1, 2007; 103(6): 2120 - 2128. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Stansfield, N. C. Moss, M. S. Willis, R. Tang, and C. H. Selzman Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion Injury Ann. Thorac. Surg., July 1, 2007; 84(1): 120 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Bates Role of Intravenous -Blockers in the Treatment of ST-Elevation Myocardial Infarction: Of Mice (Dogs, Pigs) and Men Circulation, June 12, 2007; 115(23): 2904 - 2906. [Full Text] [PDF] |
||||
![]() |
B. Ibanez, S. Prat-Gonzalez, W. S. Speidl, G. Vilahur, A. Pinero, G. Cimmino, M. J. Garcia, V. Fuster, J. Sanz, and J. J. Badimon Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance Circulation, June 12, 2007; 115(23): 2909 - 2916. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Pierre, C. Yang, Z. Yuan, J. Seminerio, C. Mouas, K. D. Garlid, P. Dos-Santos, and Z. Xie Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts Cardiovasc Res, February 1, 2007; 73(3): 488 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Southerland, D. M. Milhorn, R. D. Foreman, B. Linderoth, M. J. L. DeJongste, J. A. Armour, V. Subramanian, M. Singh, K. Singh, and J. L. Ardell Preemptive, but not reactive, spinal cord stimulation mitigates transient ischemia-induced myocardial infarction via cardiac adrenergic neurons Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H311 - H317. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Saini and N. S. Dhalla Modification of intracellular calcium concentration in cardiomyocytes by inhibition of sarcolemmal Na+/H+ exchanger Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2790 - H2800. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kloner, M. B. Forman, R. J. Gibbons, A. M. Ross, R. W. Alexander, and G. W. Stone Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial Eur. Heart J., October 2, 2006; 27(20): 2400 - 2405. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Goyagi, T. Kimura, T. Nishikawa, Y. Tobe, and Y. Masaki {beta}-Adrenoreceptor Antagonists Attenuate Brain Injury After Transient Focal Ischemia in Rats. Anesth. Analg., September 1, 2006; 103(3): 658 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, G. Marggraf, M. Neuhauser, J. Forkel, U. Herold, M. Kamler, P. Massoudy, and H. Jakob Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 285 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Du, S. Jovanovic, A. Clelland, A. Sukhodub, G. Budas, K. Phelan, V. Murray-Tait, L. Malone, and A. Jovanovic Overexpression of SUR2A generates a cardiac phenotype resistant to ischemia FASEB J, June 1, 2006; 20(8): 1131 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takeda, M. Akao, M. Matsumoto-Ida, M. Kato, H. Takenaka, Y. Kihara, T. Kume, A. Akaike, and T. Kita Serofendic Acid, a Novel Substance Extracted From Fetal Calf Serum, Protects Against Oxidative Stress in Neonatal Rat Cardiac Myocytes J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1882 - 1890. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kloner and S. H. Rezkalla Preconditioning, postconditioning and their application to clinical cardiology Cardiovasc Res, May 1, 2006; 70(2): 297 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Terkelsen, B. L. Norgaard, J. F. Lassen, S. H. Poulsen, J. C. Gerdes, E. Sloth, L. B.-H. Gotzsche, F. K. Romer, L. Thuesen, T. T. Nielsen, et al. Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study) Eur. Heart J., February 1, 2006; 27(3): 267 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Reesink, L. D.C. Sauren, A. L.A.J. Dekker, E. Severdija, T. van der Nagel, G. G. Geskes, F. H. van der Veen, and J. G. Maessen Synchronously counterpulsating extracorporeal life support enhances myocardial working conditions regardless of systemic perfusion pressure Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 790 - 796. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, P. Massoudy, M. Neuhauser, S. Knipp, M. Kamler, J. Piotrowski, K. Mann, and H. Jakob Prognostic Value of Preoperative Cardiac Troponin I in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Chest, November 1, 2005; 128(5): 3526 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tan, Z. Ma, L. Han, R. Du, L. Zhao, X. Wei, D. Hou, B. H. Johnstone, M. R. Farlow, and Y. Du Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2265 - H2271. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Burggren and M. G. Monticino Assessing physiological complexity J. Exp. Biol., September 1, 2005; 208(17): 3221 - 3232. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Ross, R. J. Gibbons, G. W. Stone, R. A. Kloner, R. W. Alexander, and for the AMISTAD-II Investigators A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1775 - 1780. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Shneyvays, D. Leshem, T. Zinman, L. K. Mamedova, K. A. Jacobson, and A. Shainberg Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2792 - H2801. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |